Nissui Pharmaceutical Co., Ltd. operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Nissui Pharmaceutical Co., Ltd. with three other
pharmaceutical manufacturers in Asia:
Searle Co Ltd
sales of 20.47 billion Pakistan Rupees [US$127.35 million]
Caplin Point Laboratories Limited
(8.63 billion Indian Rupees [US$116.36 million]
of which 100%
was Pharmaceuticals formulations), and
Shilpa Medicare Limited
based in INDIA
(9.08 billion Indian Rupees [US$122.39 million]
of which 98%
was Pharmaceutical products and services).
During the year ended March of 2020, sales at
Nissui Pharmaceutical Co., Ltd. were ¥12.77 billion (US$122.49 million).
a very small
increase of 1.8%
versus 2019, when the company's sales were ¥12.55 billion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Nissui Pharmaceutical Co., Ltd. had sales
of ¥11.86 billion.
Sales of Diagnostics saw an increase
2.3% in 2020, from
¥10.08 billion to ¥10.31 billion.
Not all segments of Nissui Pharmaceutical Co., Ltd. experienced an increase in sales in 2020:
sales of Pharmaceuticals fell 0.5% to ¥2.46 billion.